We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 402

Prohibition Order Upheld, Appeal re Sound Prediction and Sufficiency Dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • March 22 2017

Teva appealed a decision of the Federal Court ("FC") granting Leo a prohibition order in respect of their psoriasis drug (Decision here; our summary


Summary Judgment Motion in S. 8 Case Dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • March 15 2017

In this case, Abbott and Takeda brought a summary judgment motion as against Apotex, to dismiss the s. 8 proceeding in its entirety. As a preliminary


Patents Relating to Snowmobiles Infringed but Invalid for Insufficiency
  • Borden Ladner Gervais LLP
  • Canada
  • March 8 2017

In an action for patent infringement, the Court considered the infringement and validity of four patents, as well as remedies. The Court reviewed the


Application for Prohibition Granted for Generic Version of Concerta
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Court granted Janssen's application prohibiting the Minister of Health from issuing an NOC to Actavis for its generic version of Concerta. The


Motion for default judgment denied without affidavit evidence
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

The Plaintiffs brought a motion for default judgment after no Statement of Defence was filed and no response to the Request to Admit was provided. The


Improper priority claim is not a material allegation which renders patent void under s.53
  • Borden Ladner Gervais LLP
  • Canada
  • April 6 2016

This was a patent infringement action, relating to an invention that pertains to a fast, uniform and contactless method of crosslinking polymers


Judicial Review of Commissioner's Decision Refusing to Amend Priority Date Dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • March 1 2017

The Federal Court dismissed Bayer's application for judicial review of the Commissioner of Patents' decision refusing Bayer's request to amend the


Decision to not Remove Solicitors as Counsel for the Defendants Upheld on Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • March 1 2017

The Federal Court of Appeal upheld a decision of the Federal Court dismissing an appeal from the Prothonotary's order wherein he refused to remove


Formulation patent found not to be infringed as a redacted excipient was not a “pentahydric or hexahydric alcohol”
  • Borden Ladner Gervais LLP
  • Canada
  • April 22 2015

Apotex has successfully alleged that Teva’s patent to “Stable Compositions Containing Rasagiline” will not be infringed by Apotex’s use of a


Court enforces a settlement agreement even though one party denied such an agreement existed
  • Borden Ladner Gervais LLP
  • Canada
  • April 22 2015

Allergan brought a motion to enforce a settlement agreement that Apotex denies was made. Allergan had sued for infringement and Apotex wrote a